-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2024-512536-29-00
4
2025-02-28
Amyotrophic Lateral Sclerosis (ALS)
-
2023-506605-19-00
5
2025-02-11
Bipolar depression
-
2024-511404-17-00
5
2024-10-07
Unresectable or metastatic NRAS mutant cutaneous melanoma
-
2023-506602-39-00
6
2024-08-01
schizophrenia, schizoaffective disorder, schizophrenifom disorder
-
2023-505804-42-00
5
2024-07-10
NON SEGMENTAL VITILIGO
-
2023-504214-30-00
5
2024-06-27
Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
-
2023-503697-21-01
5
2024-06-24
Idiopathic pulmonary fibrosis
-
2023-504026-19-01
5
2024-06-05
Prostate Cancer
-
2022-502050-14-00
5
2024-06-04
Crohn's disease
-
2023-507039-39-00
5
2024-03-22
Moderate to Severe Plaque Psoriasis
-
2022-501157-36-00
6
2024-02-07
Critically ill patients who are dependent on high level medical care i
-
2022-501788-41-00
5
2023-11-14
Ulcerative Colitis
-
2023-509810-13-00
4
2023-05-13
Acute Lymphoblastic Leukemia (ALL)
-
2022-501152-28-00
4
2022-12-21
Breast Cancer
-
2022-502503-30-00
5
2022-12-15
Acute lymphoblastic leukemia
-
2023-506548-18-00
10
2022-11-10
Dermatitis atopic
-
2024-516066-11-00
5
2022-08-31
Patients with newly diagnosed, histologically confirmed, primary advan
-
2023-503465-33-00
5
2020-07-03
Cholestasis
-
2023-504694-20-00
9
2017-01-13
pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukem
-
2025-522301-37-00
4
2026-06-24
Nonsegmental vitiligo
-
2025-523096-34-00
5
2026-06-11
B-cell Acute Lymphoblastic Leukemia
-
2025-523544-12-00
5
2026-06-02
Myelodysplastic neoplasms/syndromes (MDS)
-
2023-503766-24-00
11
2026-05-26
Moderate to Severe Plaque Psoriasis